Genetic Technologies Limited (NASDAQ:GENE – Get Free Report) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 25,900 shares, a growth of 48.0% from the October 15th total of 17,500 shares. Based on an average trading volume of 15,700 shares, the short-interest ratio is presently 1.6 days.
Genetic Technologies Price Performance
GENE remained flat at $0.77 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.83 and a debt-to-equity ratio of 0.01. Genetic Technologies has a 52-week low of $0.67 and a 52-week high of $3.77. The firm has a 50 day moving average of $0.77 and a 200-day moving average of $1.20.
Institutional Trading of Genetic Technologies
An institutional investor recently bought a new position in Genetic Technologies stock. BNP Paribas Financial Markets acquired a new stake in Genetic Technologies Limited (NASDAQ:GENE – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 9,100 shares of the biotechnology company’s stock, valued at approximately $26,000. BNP Paribas Financial Markets owned about 0.24% of Genetic Technologies at the end of the most recent reporting period. Institutional investors own 0.63% of the company’s stock.
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments.
Featured Articles
- Five stocks we like better than Genetic Technologies
- Conference Calls and Individual Investors
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Financial Services Stocks Investing
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What is a Special Dividend?
- Time to Load Up on Home Builders?
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.